Dr. Fowler on FLIPI Scoring System in Follicular Lymphoma

Nathan Fowler, MD
Published: Tuesday, Feb 28, 2017



Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the FLIPI scoring system in follicular lymphoma.

FLIPI predicts disease progression in groups of patients through factors of low hemoglobin levels, stage III/IV disease, number of nodal sites, patient age, and amount of lactate dehydrogenase (LDH). It is used to determine if a group of patients will have a worse outcome overall.

Fowler emphasizes that this system looks at the group as a whole. This means that individual patients who may have a better outcome can exist within a test group—but there isn’t a way to determine who those patients are.
 
SELECTED
LANGUAGE


Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the FLIPI scoring system in follicular lymphoma.

FLIPI predicts disease progression in groups of patients through factors of low hemoglobin levels, stage III/IV disease, number of nodal sites, patient age, and amount of lactate dehydrogenase (LDH). It is used to determine if a group of patients will have a worse outcome overall.

Fowler emphasizes that this system looks at the group as a whole. This means that individual patients who may have a better outcome can exist within a test group—but there isn’t a way to determine who those patients are.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x